Transport properties of anyons in random topological environments

The quasi one-dimensional transport of Abelian and non-Abelian anyons is studied in the presence of a random topological background. In particular, we consider the quantum walk of an anyon that braids around islands of randomly filled static anyons of the same type. Two distinct behaviours are identified. We analytically demonstrate that all types of Abelian anyons localise purely due to the statistical phases induced by their random anyonic environment. In contrast, we numerically show that non-Abelian Ising anyons do not localise. This is due to their entanglement with the anyonic environment that effectively induces dephasing. Our study demonstrates that localisation properties strongly depend on non-local topological interactions and it provides a clear distinction in the transport properties of Abelian and non-Abelian statistics.Comment: 9 pages, 5 figure

Braiding Interactions in Anyonic Quantum Walks

The anyonic quantum walk is a dynamical model describing a single anyon propagating along a chain of stationary anyons and interacting via mutual braiding statistics. We review the recent results on the effects of braiding statistics in anyonic quantum walks in quasi-one dimensional ladder geometries. For anyons which correspond to spin-1/2 irreps of the quantum groups $SU(2)_k$, the non-Abelian species $(1<k<\infty)$ gives rise to entanglement between the walker and topological degrees of freedom which is quantified by quantum link invariants over the trajectories of the walk. The decoherence is strong enough to reduce the walk on the infinite ladder to classical like behaviour. We also present numerical results on mixing times of $SU(2)_2$ or Ising model anyon walks on cyclic graphs. Finally, the possible experimental simulation of the anyonic quantum walk in Fractional Quantum Hall systems is discussed.Comment: 13 pages, submitted to Proceedings of the 2nd International Conference on Theoretical Physics (ICTP 2012

Distant galaxy clusters in the COSMOS field found by HIROCS

We present the first high-redshift galaxy cluster candidate sample from the HIROCS survey found in the COSMOS field. It results from a combination of public COSMOS with proprietary H-band data on a 0.66 square degree part of the COSMOS field and comprises 12 candidates in the redshift range 1.23 < z < 1.55. We find an increasing fraction of blue cluster members with increasing redshift. Many of the blue and even some of the reddest member galaxies exhibit disturbed morphologies as well as signs of interaction.Comment: 5 pages, 5 figures, in print format, accepted for publication by A&A Letter

Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand

We have constructed an artificial ligand for the hepatocyte-specific asialoglycoprotein receptor for the purpose of generating a synthetic delivery system for DNA. This ligand has a tetra-antennary structure, containing four terminal galactose residues on a branched carrier peptide. The carbohydrate residues of this glycopeptide were introduced by reductive coupling of lactose to the alpha- and epsilon-amino groups of the two N-terminal lysines on the carrier peptide. The C-terminus of the peptide, containing a cysteine separated from the branched N-terminus by a 10 amino acid spacer sequence, was used for conjugation to 3-(2-pyridyldithio)propionate-modified polylysine via disulfide bond formation. Complexes containing plasmid DNA bound to these galactose-polylysine conjugates have been used for asialoglycoprotein receptor-mediated transfer of a luciferase gene into human (HepG2) and murine (BNL CL.2) hepatocyte cell lines. Gene transfer was strongly promoted when amphipathic peptides with pH-controlled membrane-disruption activity, derived from the N-terminal sequence of influenza virus hemagglutinin HA-2, were also present in these DNA complexes. Thus, we have essentially borrowed the small functional domains of two large proteins, asialoglycoprotein and hemagglutinin, and assembled them into a supramolecular complex to generate an efficient gene-transfer system

Combined Medetomidine and Ketamine for Short-term Anaesthesia in Ferrets -a Clinical Study

Abstract Rau‰er P., J. Zatloukal, A. Neãas, J. Lorenzová, L. Lexmaulová: Combined Medetomidine and Ketamine for Short-term Anaesthesia in Ferrets -a Clinical Study. Acta Vet. Brno 2002, 71: 243-248. In a clinical study we evaluated the quality of anaesthesia by a combination of medetomidine and ketamine given at two different doses to perform standard surgical procedures in the ferret (e.g., anal sac removal, castration or ovariohysterectomy). Ferrets were intramuscularly administered medetomidine (60 µg/kg) in a combination with ketamine given at two different doses (5 mg/kg in group A and 8 mg/kg in group B). Within several minutes all animals took up lateral recumbency, lost bottle the palpebral reflex and deep sensation except for three individuals receiving the lower ketamine dose, in which there was no deep sensation loss observed. Lower ketamin dose resulted in later loss of all evaluated parameters. It also reduced the time of their recovery (especially deep sensation). The loss of deep sensation after the higher ketamine dose was nearly twice as long as after the lower dose. Heart rate values were comparable in both groups and showed a decreasing tendency as well as the respiratory rate, which, however, differed in both groups from the 30 th min of anaesthesia. The combination of medetomidine and ketamine is very effective for the anaesthesia in ferrets regarding the duration, myorelaxation and analgesia. Prolongation of this anaesthesia is possible with half ketamine doses. α-adrenergic drugs; dissociative anesthetic

iP & OEIP - Cytokinin Micro Application Modulates Root Development with High Spatial Resolution

State-of-the-art technology based on organic electronics can be used as a flow-free delivery method for organic substances with high spatial resolution. Such highly targeted drug micro applications can be used in plant research for the regulation of physiological processes on tissue and cellular levels. Here, for the first time, an organic electronic ion pump (OEIP) is reported that can transport an isoprenoid-type cytokinin, N-6-isopentenyladenine (iP), to intact plants. Cytokinins (CKs) are plant hormones involved in many essential physiological processes, including primary root (PR) and lateral root (LR) development. Using the Arabidopsis thaliana root as a model system, efficient iP delivery is demonstrated with a biological output - cytokinin-related PR and LR growth inhibition. The spatial resolution of iP delivery, defined for the first time for an organic compound, is shown to be less than 1 mm, exclusively affecting the OEIP-targeted LR. Results from the application of the high-resolution OIEP treatment method confirm previously published findings showing that the influence of CKs may vary at different stages of LR development. Thus, OEIP-based technologies offer a novel, electronically controlled method for phytohormone delivery that could contribute to unraveling cytokinin functions during different developmental processes with high specificity

Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.

OBJECTIVES: The primary objective of this study is to test the hypothesis that administration of dexamethasone 20 mg is superior to a 6 mg dose in adult patients with moderate or severe ARDS due to confirmed COVID-19. The secondary objective is to investigate the efficacy and safety of dexamethasone 20 mg versus dexamethasone 6 mg. The exploratory objective of this study is to assess long-term consequences on mortality and quality of life at 180 and 360 days. TRIAL DESIGN: REMED is a prospective, phase II, open-label, randomised controlled trial testing superiority of dexamethasone 20 mg vs 6 mg. The trial aims to be pragmatic, i.e. designed to evaluate the effectiveness of the intervention in conditions that are close to real-life routine clinical practice. PARTICIPANTS: The study is multi-centre and will be conducted in the intensive care units (ICUs) of ten university hospitals in the Czech Republic. INCLUSION CRITERIA: Subjects will be eligible for the trial if they meet all of the following criteria: 1. Adult (≥18 years of age) at time of enrolment; 2. Present COVID-19 (infection confirmed by RT-PCR or antigen testing); 3. Intubation/mechanical ventilation or ongoing high-flow nasal cannula (HFNC) oxygen therapy; 4. Moderate or severe ARDS according to Berlin criteria:  • Moderate - PaO2/FiO2 100-200 mmHg;  • Severe - PaO2/FiO2 < 100 mmHg; 5. Admission to ICU in the last 24 hours. EXCLUSION CRITERIA: Subjects will not be eligible for the trial if they meet any of the following criteria: 1. Known allergy/hypersensitivity to dexamethasone or excipients of the investigational medicinal product (e.g. parabens, benzyl alcohol); 2. Fulfilled criteria for ARDS for ≥14 days at enrolment; 3. Pregnancy or breastfeeding; 4. Unwillingness to comply with contraception measurements from enrolment until at least 1 week after the last dose of dexamethasone (sexual abstinence is considered an adequate contraception method); 5. End-of-life decision or patient is expected to die within next 24 hours; 6. Decision not to intubate or ceilings of care in place; 7. Immunosuppression and/or immunosuppressive drugs in medical history:  a) Systemic immunosuppressive drugs or chemotherapy in the past 30 days;  b) Systemic corticosteroid use before hospitalization;  c) Any dose of dexamethasone during the present hospital stay for COVID-19 for ≥5 days before enrolment;  d) Systemic corticosteroids during present hospital stay for conditions other than COVID-19 (e.g. septic shock); 8. Current haematological or generalized solid malignancy; 9. Any contraindication for corticosteroid administration, e.g.  • intractable hyperglycaemia;  • active gastrointestinal bleeding;  • adrenal gland disorders;  • presence of superinfection diagnosed with locally established clinical and laboratory criteria without adequate antimicrobial treatment; 10. Cardiac arrest before ICU admission; 11. Participation in another interventional trial in the last 30 days. INTERVENTION AND COMPARATOR: Dexamethasone solution for injection/infusion is the investigational medicinal product as well as the comparator. The trial will assess two doses, 20 mg (investigational) vs 6 mg (comparator). Patients in the intervention group will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. Patients in the control group will receive dexamethasone 6 mg day 1-10. All authorized medicinal products containing dexamethasone in the form of solution for i.v. injection/infusion can be used. MAIN OUTCOMES: Primary endpoint: Number of ventilator-free days (VFDs) at 28 days after randomisation, defined as being alive and free from mechanical ventilation. SECONDARY ENDPOINTS: a) Mortality from any cause at 60 days after randomisation; b) Dynamics of inflammatory marker (C-Reactive Protein, CRP) change from Day 1 to Day 14; c) WHO Clinical Progression Scale at Day 14; d) Adverse events related to corticosteroids (new infections, new thrombotic complications) until Day 28 or hospital discharge; e) Independence at 90 days after randomisation assessed by Barthel Index. The long-term outcomes of this study are to assess long-term consequences on mortality and quality of life at 180 and 360 days through telephone structured interviews using the Barthel Index. RANDOMISATION: Randomisation will be carried out within the electronic case report form (eCRF) by the stratified permuted block randomisation method. Allocation sequences will be prepared by a statistician independent of the study team. Allocation to the treatment arm of an individual patient will not be available to the investigators before completion of the whole randomisation process. The following stratification factors will be applied: • Age <65 and ≥ 65; • Charlson Comorbidity index (CCI) <3 and ≥3; • CRP <150 mg/L and ≥150 mg/L • Trial centre. Patients will be randomised in a 1 : 1 ratio into one of the two treatment arms. Randomisation through the eCRF will be available 24 hours every day. BLINDING (MASKING): This is an open-label trial in which the participants and the study staff will be aware of the allocated intervention. Blinded pre-planned statistical analysis will be performed. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The sample size is calculated to detect the difference of 3 VFDs at 28 days (primary efficacy endpoint) between the two treatment arms with a two-sided type I error of 0.05 and power of 80%. Based on data from a multi-centre randomised controlled trial in COVID-19 ARDS patients in Brazil and a multi-centre observational study from French and Belgian ICUs regarding moderate to severe ARDS related to COVID-19, investigators assumed a standard deviation of VFD at 28 days as 9. Using these assumptions, a total of 142 patients per treatment arm would be needed. After adjustment for a drop-out rate, 150 per treatment arm (300 patients per study) will be enrolled. TRIAL STATUS: This is protocol version 1.1, 15.01.2021. The trial is due to start on 2 February 2021 and recruitment is expected to be completed by December 2021. TRIAL REGISTRATION: The study protocol was registered on EudraCT No.:2020-005887-70, and on December 11, 2020 on ClinicalTrials.gov (Title: Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19 (REMED)) Identifier: NCT04663555 with a last update posted on February 1, 2021. FULL PROTOCOL: The full protocol (version 1.1) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the standard formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol